BACKGROUND: We investigated 18-month incidence and determinants of death and loss to follow-up of children after antiretroviral therapy (ART) initiation in a multiregional collaboration in lower-income countries. METHODS: HIV-infected children (positive polymerase chain reaction <18 months or positive serology ≥18 months) from International Epidemiologic Databases to Evaluate AIDS cohorts, <16 years, initiating ART were eligible. A competing risk regression model was used to analyze the independent risk of 2 failure types: death and loss to follow-up (>6 months). FINDINGS: Data on 13,611 children, from Asia (N = 1454), East Africa (N = 3114), Southern Africa (N = 6212), and West Africa (N = 2881) contributed 20,417 person-years of follow-up. At 18 months, the adjusted risk of death was 4.3% in East Africa, 5.4% in Asia, 5.7% in Southern Africa, and 7.4% in West Africa (P = 0.01). Age < 24 months, World Health Organization stage 4, CD4 < 10%, attending a private sector clinic, larger cohort size, and living in West Africa were independently associated with poorer survival. The adjusted risk of loss to follow-up was 4.1% in Asia, 9.0% in Southern Africa, 14.0% in East Africa, and 21.8% in West Africa (P < 0.01). Age < 12 months, nonnucleoside reverse transcriptase inhibitor I-based ART regimen, World Health Organization stage 4 at ART start, ART initiation after 2005, attending a public sector or a nonurban clinic, having to pay for laboratory tests or antiretroviral drugs, larger cohort size, and living in East Africa or West Africa were significantly associated with higher loss to follow-up. CONCLUSIONS: Findings differed substantially across regions but raise overall concerns about delayed ART start, low access to free HIV services for children, and increased workload on program retention in lower-income countries. Universal free access to ART services and innovative approaches are urgently needed to improve pediatric outcomes at the program level.
BACKGROUND: We investigated 18-month incidence and determinants of death and loss to follow-up of children after antiretroviral therapy (ART) initiation in a multiregional collaboration in lower-income countries. METHODS:HIV-infectedchildren (positive polymerase chain reaction <18 months or positive serology ≥18 months) from International Epidemiologic Databases to Evaluate AIDS cohorts, <16 years, initiating ART were eligible. A competing risk regression model was used to analyze the independent risk of 2 failure types: death and loss to follow-up (>6 months). FINDINGS: Data on 13,611 children, from Asia (N = 1454), East Africa (N = 3114), Southern Africa (N = 6212), and West Africa (N = 2881) contributed 20,417 person-years of follow-up. At 18 months, the adjusted risk of death was 4.3% in East Africa, 5.4% in Asia, 5.7% in Southern Africa, and 7.4% in West Africa (P = 0.01). Age < 24 months, World Health Organization stage 4, CD4 < 10%, attending a private sector clinic, larger cohort size, and living in West Africa were independently associated with poorer survival. The adjusted risk of loss to follow-up was 4.1% in Asia, 9.0% in Southern Africa, 14.0% in East Africa, and 21.8% in West Africa (P < 0.01). Age < 12 months, nonnucleoside reverse transcriptase inhibitor I-based ART regimen, World Health Organization stage 4 at ART start, ART initiation after 2005, attending a public sector or a nonurban clinic, having to pay for laboratory tests or antiretroviral drugs, larger cohort size, and living in East Africa or West Africa were significantly associated with higher loss to follow-up. CONCLUSIONS: Findings differed substantially across regions but raise overall concerns about delayed ART start, low access to free HIV services for children, and increased workload on program retention in lower-income countries. Universal free access to ART services and innovative approaches are urgently needed to improve pediatric outcomes at the program level.
Authors: Delphine Sauvageot; Myrto Schaefer; David Olson; Mar Pujades-Rodriguez; Daniel P O'Brien Journal: Pediatrics Date: 2010-04-12 Impact factor: 7.124
Authors: M-F Anaky; J Duvignac; L Wemin; A Kouakoussui; S Karcher; S Touré; C Seyler; P Fassinou; F Dabis; T N'Dri-Yoman; X Anglaret; V Leroy Journal: Bull World Health Organ Date: 2009-12-21 Impact factor: 9.408
Authors: Lukas Fenner; Martin W G Brinkhof; Olivia Keiser; Ralf Weigel; Morna Cornell; Harry Moultrie; Hans Prozesky; Karl Technau; Brian Eley; Paula Vaz; Margaret Pascoe; Janet Giddy; Gilles Van Cutsem; Robin Wood; Matthias Egger; Mary-Ann Davies Journal: J Acquir Immune Defic Syndr Date: 2010-08 Impact factor: 3.731
Authors: Rachel C Vreeman; Winstone M Nyandiko; Samwel O Ayaya; Eunice G Walumbe; David G Marrero; Thomas S Inui Journal: AIDS Patient Care STDS Date: 2010-10 Impact factor: 5.078
Authors: Mary-Ann Davies; Harry Moultrie; Brian Eley; Helena Rabie; Gilles Van Cutsem; Janet Giddy; Robin Wood; Karl Technau; Olivia Keiser; Matthias Egger; Andrew Boulle Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Elvin H Geng; Denis Nash; Andrew Kambugu; Yao Zhang; Paula Braitstein; Katerina A Christopoulos; Winnie Muyindike; Mwebesa Bosco Bwana; Constantin T Yiannoutsos; Maya L Petersen; Jeffrey N Martin Journal: Curr HIV/AIDS Rep Date: 2010-11 Impact factor: 5.071
Authors: Marielle Bemelmans; Thomas van den Akker; Nathan Ford; Mit Philips; Rony Zachariah; Anthony Harries; Erik Schouten; Katharina Hermann; Beatrice Mwagomba; Moses Massaquoi Journal: Trop Med Int Health Date: 2010-10-19 Impact factor: 2.622
Authors: Matthias Egger; Ben D Spycher; John Sidle; Ralf Weigel; Elvin H Geng; Matthew P Fox; Patrick MacPhail; Gilles van Cutsem; Eugène Messou; Robin Wood; Denis Nash; Margaret Pascoe; Diana Dickinson; Jean-François Etard; James A McIntyre; Martin W G Brinkhof Journal: PLoS Med Date: 2011-01-18 Impact factor: 11.069
Authors: Luisa Salazar-Vizcaya; Olivia Keiser; Mary-Ann Davies; Andreas D Haas; Nello Blaser; Vivian Cox; Brian Eley; Helena Rabie; Harry Moultrie; Janet Giddy; Robin Wood; Matthias Egger; Janne Estill Journal: AIDS Date: 2014-10-23 Impact factor: 4.177
Authors: Edwin Masese Machine; Susan L Gillespie; Nuria Homedes; Beatrice J Selwyn; Michael W Ross; Gabriel Anabwani; Gordon Schutze; Mark W Kline Journal: AIDS Care Date: 2016-05-10
Authors: Mireille Porter; Mary-Ann Davies; Muntanga K Mapani; Helena Rabie; Sam Phiri; James Nuttall; Lee Fairlie; Karl-Günter Technau; Kathryn Stinson; Robin Wood; Maureen Wellington; Andreas D Haas; Janet Giddy; Frank Tanser; Brian Eley Journal: J Acquir Immune Defic Syndr Date: 2015-08-15 Impact factor: 3.731
Authors: Nora M McCormick; Nan Li; David Sando; Aisa Muya; Karim P Manji; Rodrick Kisenge; Christopher Duggan; Guerino Chalamilla; Wafaie W Fawzi; Donna Spiegelman Journal: J Acquir Immune Defic Syndr Date: 2015-11-01 Impact factor: 3.731